Pisano E D, Earp J A, Gallant T L
Department of Radiology, University of North Carolina (UNC) School of Medicine, Chapel Hill, USA.
Cancer Detect Prev. 1998;22(2):161-7. doi: 10.1046/j.1525-1500.1998.cdoa21.x.
This pilot study describes women's interpretations of the experience of a false positive mammogram followed by a negative biopsy and the impact of this experience on subsequent participation in screening mammography. A 25-min, open-ended telephone interview was administered in 1992 to 30 women over age 39 who had negative biopsies in 1987 preceded by abnormal mammograms. Almost twice as many women reported getting regular mammograms after the biopsy (60%) as did before 1987 (33%). Most received their next mammogram after the biopsy within the recommended interval (73%), and those getting regular mammograms prior to the biopsy experience were more likely than those who did not have a prior habit of undergoing mammography to continue to get them afterwards. These preliminary findings suggest that a negative breast biopsy after a positive mammogram does not reduce a patient's likelihood of undergoing screening in the future. In fact, it may serve as an impetus for increased compliance with screening recommendations.
这项试点研究描述了女性对乳腺钼靶检查结果为假阳性随后活检结果为阴性这一经历的解读，以及该经历对其后续参与乳腺钼靶筛查的影响。1992年，对30名39岁以上的女性进行了一次25分钟的开放式电话访谈，这些女性在1987年乳腺钼靶检查异常后活检结果为阴性。报告在活检后定期进行乳腺钼靶检查的女性（60%）几乎是1987年之前（33%）的两倍。大多数女性在活检后的推荐间隔内进行了下一次乳腺钼靶检查（73%），并且在活检前有定期进行乳腺钼靶检查习惯的女性比没有这种习惯的女性更有可能在之后继续进行检查。这些初步发现表明，乳腺钼靶检查阳性后活检结果为阴性并不会降低患者未来接受筛查的可能性。事实上，它可能会促使患者更积极地遵守筛查建议。
